IN THE CLAIMS:

Please amend the claims as follows.

1 – 3. (Cancelled).

4. (Original) An aporphine compound having the following structure IV:



IV

wherein R_1, R_2, R_5 and R_6 are each selected from H, OH, O-acyl, OMe, OEt, O^nPr and O^iPr; R_3 and R_4 are each selected from H, OH, O-acyl, OMe, F, Cl, Br, NH_2, NO_2 and CN; and R_7 is selected from H, OH, O-acyl and OMe.

5 – 8. (Cancelled).

9. (Currently Amended) ~~The aporphine compound of claim 1, wherein the aporphine compound is in a~~ A pharmaceutical composition for ~~preventing or~~ treating an ischemic disease that is responsive to an expression level of epithelial nitric oxide synthase (eNOS), wherein the pharmaceutical composition comprises an effective amount of ~~the~~ an aporphine compound having a structure shown in formula (I) below and a pharmaceutically acceptable carrier or excipient[[.]].



I

wherein R_1, R_2, R_6 and R_7 are each selected from H, OH, O-acyl, OMe, OEt, O^nPr, and

O^iPr; R_3 and R_5 are each selected from H, OH, O-acyl, OMe, F, Cl, Br, NH_2, NO_2 and CN; R_4 is selected from allyl and C_nH_{2n+1}, $n \geqslant 0$; and R_8 is selected from H, OH and OMe.

10 – 11. (Cancelled).

12. (Currently Amended) ~~The aporphine compound of claim 4, wherein the aporphine compound is in a~~ A pharmaceutical composition for ~~preventing or~~ treating an ischemic disease that is responsive to an expression level of epithelial nitric oxide synthase (eNOS), wherein the pharmaceutical composition comprises an effective amount of ~~the~~ an aporphine compound having a structure shown as formula (IV) below and a pharmaceutically acceptable carrier or excipient[[.]],



IV

wherein R_1, R_2, R_5 and R_6 are each selected from H, OH, O-acyl, OMe, OEt, O^nPr and O^iPr; R_3 and R_4 are each selected from H, OH, O-acyl, OMe, F, Cl, Br, NH_2, NO_2 and CN; and R_7 is selected from H, OH, O-acyl and OMe.

13 – 14. (Cancelled).

15. (Currently Amended) ~~The oxoaporphine compound of claim 7, wherein the oxoaporphine compound is in a~~ A pharmaceutical composition for ~~preventing or~~ treating an ischemic disease that is responsive to an expression level of epithelial nitric oxide synthase (eNOS), wherein the pharmaceutical composition comprises an effective amount of ~~the~~ an aporphine compound having a structure shown as formula (VII) below and a pharmaceutically acceptable carrier or excipient[[.]],



VII

wherein R_1, R_2, R_5 and R_6 are each selected from H, OH, O-acyl, OMe, OEt, O^nPr and O^iPr; R_3 and R_4 are each selected from H, OH, O-acyl, OMe, F, Cl, Br, NO_2 and CN; and R_7 is selected from H, OH, O-acyl and OMe.

16. (Cancelled).

17. (New) The pharmaceutical composition of claim 9, wherein the ischemic disease is one of ischemic stroke, ischemic cerebral apoplexy, ischemic cerebral thrombosis, ischemic cerebral embolism, hypoxic ischemic encephalopathy, ischemic cardiac disease, and ischemic enteropathy.

18. (New) The pharmaceutical composition of claim 12, wherein the ischemic disease is one of ischemic stroke, ischemic cerebral apoplexy, ischemic cerebral thrombosis, ischemic cerebral embolism, hypoxic ischemic encephalopathy, ischemic cardiac disease, and ischemic enteropathy.

19. (New) The pharmaceutical composition of claim 15, wherein the ischemic disease is one of ischemic stroke, ischemic cerebral apoplexy, ischemic cerebral thrombosis, ischemic cerebral embolism, hypoxic ischemic encephalopathy, ischemic cardiac disease, and ischemic enteropathy.